Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
Open accessThe DOI matches its Crossref record; 242 of the 246 references it cites were found in a registry or an index.
Abstract
Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and oxygen supply to the tumor cells through the decrease of the vascular network and the avoidance of new blood vessels formation. Most of the anti-angiogenic agents approved for cancer treatment rely on targeting vascular endothelial growth factor (VEGF) actions, as VEGF signaling is considered the main angiogenesis promotor. In addition to the control of angiogenesis, these drugs can potentiate immune therapy as VEGF also exhibits immunosuppressive functions. Despite the mechanistic rational that strongly supports the benefit of drugs to stop cancer progression, they revealed to be insufficient in most cases. We hypothesize that the rehabilitation of old drugs that interfere with mechanisms of angiogenesis related to tumor microenvironment might represent a promising strategy. In this review, we deepened research on the molecular mechanisms underlying anti-angiogenic strategies and their failure and went further into the alternative mechanisms that impact angiogenesis. We concluded that the combinatory targeting of alternative effectors of angiogenic pathways might be a putative solution for anti-angiogenic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tyrosine kinase inhibitors (TKIs) have broadened the scope of anti-angiogenic therapy to include other pro-angiogenic growth factors and receptors such as PDGFR, FGFR, c-MET, and PIGF, which are now mainstay targets of the targeted therapy arsenal (Table 2) [33].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [33]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Park, S. Y., Kang, J. H., Jeong, K. J., Lee, J., Han, J. W., Choi, W. S., Kim, Y. K., Kang, J., Park, C. G., & Lee, H. Y. (2011) · International Journal of Cancer · doi:10.1002/ijc.25589 · Cited by 135
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 2×
“The blockage of the VEGF:VEGFR axis seems to be ineffective as monotherapy, and primary or de novo resistance is a common feature in cancer patients [23,123].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“These strategies have focused mainly on eye disease [110] and wound healing [111], but their application in cancer therapy is under debate [112,113].”
BackgroundAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733 · cited 1×
“on tumor growth and an increase in OS [161].”
BackgroundVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605 · cited 1×
“Moreover, the design and development of new anti-VEGF signaling drugs continues, including the arylamide-5-anilinoquinazoline-8nitro derivative a recent inhibitor of VEGFR2-kinase activity with in vitro anti-tumor and anti-angiogenic activity [38].”
BackgroundFundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Research works printed but not linked: 1
- 5. Domingues, G.; Fernandes, S.G.; Serpa, J. Dynamics of VEGF-A and its Receptors in Cancer Vascularization-An Overview. In Understand Cancer: Research and Treatment ; iConcept Press: Hong Kong, China, Chapter 3; 2015; ISBN 978-1-922227-386.
Cited by
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175586 · Cited by 362
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
VEGF signaling: Role in angiogenesis and beyond
Shaw, P., Dwivedi, S. K. D., Bhattacharya, R., Mukherjee, P., & Rao, G. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189079 · Cited by 215
Fang, J., Lu, Y., Zheng, J., Jiang, X., Shen, H., Shang, X., Lu, Y., & Fu, P. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06119-x · Cited by 209
“Most of these agents disrupt the VEGF signaling pathways involved in ECs proliferation and migration, effectively impeding tumor growth [221].”
BackgroundPatil, T. P., Vibhute, A., Patil, S. L., Dongale, T. D., & Pandey-Tiwari, A. (2023) · Applied Surface Science Advances · doi:10.1016/j.apsadv.2023.100372 · Cited by 135
Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies
Liu, X., Zhang, J., Yi, T., Li, H., Tang, X., Liu, D., Wu, D., & Li, Y. (2025) · Biomarker Research · doi:10.1186/s40364-025-00779-x · Cited by 134
“This not only reflects the central role of VEGF/VEGFRs signaling pathway in the process of tumor angiogenesis [216], but also reflects the limitations and challenges of existing therapeutic strategies.”
Reshaping of the tumor microenvironment by cellular senescence: An opportunity for senotherapies
D’Ambrosio, M., & Gil, J. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.05.010 · Cited by 119
Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy
Shao, X., Zhao, X., Wang, B., Fan, J., Wang, J., & An, H. (2025) · Theranostics · doi:10.7150/thno.103636 · Cited by 112
The Role of Inflammation and Therapeutic Concepts in Diabetic Retinopathy—A Short Review
Gomułka, K., & Ruta, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021024 · Cited by 108
“Drugs such as aflibercept (binds to circulating VEGF and acts like a “VEGF trap”), bevacizumab and ranibizumab (recombinant humanized monoclonal antibodies that blocks angiogenesis by inhibiting VEGF), or pegaptanib (a pegylated anti-VEGF aptamer, a single strand of nucleic acid that binds to the 165 isoform of VEGF)…”
BackgroundAdhesion, metastasis, and inhibition of cancer cells: a comprehensive review
Yayan, J., Franke, K.-J., Berger, M. P., Windisch, W., & Rasche, K. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-08920-5 · Cited by 100
“Bevacizumab has been used in clinical trials to inhibit angiogenesis and thereby limit metastasis [ 86 ].”
MethodCurrent status and advances of immunotherapy in nasopharyngeal carcinoma
Xu, J., Wei, X., Wang, Y., & Wang, F. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221096214 · Cited by 84
Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors
Kang, Y., Li, H., Liu, Y., & Li, Z. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05714-5 · Cited by 85
“In patients with metastatic renal cell carcinoma, intra-tumoral antigen-specific CD8 + T cell migration has been found to increase when combined with bevacizumab and atezolizumab (anti-PD-L1) (Lopes-Coelho et al. 2021).”
BackgroundTuli, H. S., Kumar, A., Ramniwas, S., Coudhary, R., Aggarwal, D., Kumar, M., Sharma, U., Parashar, N. C., Haque, S., & Sak, K. (2022) · Molecules · doi:10.3390/molecules27217653 · Cited by 75
Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 74
Sherafat, N. S., Keshavarz, A., Mardi, A., Mohammadiara, A., Aghaei, M., Maleki, L. A., & Mohammadi, M. H. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01751-7 · Cited by 69
“In addition to controlling angiogenesis, these drugs can enhance immunotherapy efficacy because VEGF also has immunosuppressive effects [43].”
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Watabe, T., Takahashi, K., Pietras, K., & Yoshimatsu, Y. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.04.007 · Cited by 67
RetractedInhibiting Angiogenesis by Anti-Cancer Saponins: From Phytochemistry to Cellular Signaling Pathways
Majnooni, M. B., Fakhri, S., Ghanadian, S. M., Bahrami, G., Mansouri, K., Iranpanah, A., Farzaei, M. H., & Mojarrab, M. (2023) · Metabolites · doi:10.3390/metabo13030323 · Cited by 63
“Today, the inhibition of angiogenesis is used as a new and practical idea to control the growth and metastasis of tumors [11].”
MethodAngiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice
Yang, S., Fang, Y., Ma, Y., Wang, F., Wang, Y., Jia, J., Yang, Y., Sun, W., Zhou, Q., & Li, Z. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70313 · Cited by 71
Wei, K., Louis, H., Emori, W., Idante, P. S., Agwamba, E. C., Cheng, C., Eno, E. A., & Unimuke, T. O. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.132795 · Cited by 57
The immunometabolic ecosystem in cancer
Bantug, G. R., & Hess, C. (2023) · Nature Immunology · doi:10.1038/s41590-023-01675-y · Cited by 61
“…could also be combined with drug-based strategies that deplete or inhibit activities of tumor-supporting cells (for example, CSF1R inhibitors) 164 , modify tumor stroma (using anti-fibrotic and antiangiogenic agents) 165,166 , or enhance antitumor T cell function (checkpoint inhibitors) 167 .”
BackgroundRole of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies
Pathak, A., Pal, A. K., Roy, S., Nandave, M., & Jain, K. (2024) · Stem Cells International · doi:10.1155/2024/9077926 · Cited by 60
“…of antiangiogenic agents for cancer therapy that these antiangiogenic agents could prevent the formation of new blood vessels and disrupt the existing one by neutralizing the angiogenic protein, inducing EC apoptosis, or inhibiting the endothelial receptors for angiogenic proteins [81].”
BackgroundLiu, X., Mei, W., Zhang, P., & Zeng, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107123 · Cited by 60
Novel EPR-enhanced strategies for targeted drug delivery in pancreatic cancer: An update
Mohammadzadeh, V., Rahiman, N., Hosseinikhah, S. M., Barani, M., Rahdar, A., Jaafari, M. R., Sargazi, S., Zirak, M. R., Pandey, S., Bhattacharjee, R., et al. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103459 · Cited by 50
Emerging applications of anti-angiogenic nanomaterials in oncotherapy
Tang, B., Ma, W., & Lin, Y. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.10.022 · Cited by 52
Wang, Z., & Yang, L. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107150 · Cited by 51
Liu, Y., Wang, Z., Tang, Z., Fu, Y. S., & Wang, L. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230817102104 · Cited by 50
“A growing number of studies tend to combine antivascular therapy with immunotherapy [25-27].”
BackgroundRecent Advances in Cell Sheet Engineering: From Fabrication to Clinical Translation
Thummarati, P., Laiwattanapaisal, W., Nitta, R., Fukuda, M., Hassametto, A., & Kino‐oka, M. (2023) · Bioengineering · doi:10.3390/bioengineering10020211 · Cited by 49
STAT3: Key targets of growth-promoting receptor positive breast cancer
Jiang, R., Zhu, J., Zhang, H., Yuan, Y. J., Dong, Z.-X., Zhou, H., & Wang, X. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03541-9 · Cited by 48
“…growth factor, HGF), adhesion factors (integrins and cadherins), proteases (matrix metalloproteinases), extra-cellular matrix proteins (fibronectin and collagen), transcription factors (hypoxia-inducible factor and nuclear factor), angiogenin, angiostatin, endostatin, and inter-leukins [160].”
BackgroundNovel roles of PIWI proteins and PIWI-interacting RNAs in human health and diseases
Wu, Z., Yu, X., Zhang, S., He, Y., & Guo, W. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01368-x · Cited by 44
Mei, C., Gong, W., Wang, X., Lv, Y., Zhang, Y., Wu, S., & Zhu, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1147717 · Cited by 46
Mimicking and analyzing the tumor microenvironment
Crouigneau, R., Li, Y., Auxillos, J., Gonçalves‐Alves, E., Marie, R., Sandelin, A., & Pedersen, S. F. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100866 · Cited by 53
“30 31–33 A promising form of TME interference is immuno-oncology approaches that restore anticancer immune response, such as anti-PD-L1/PD or CTLA4 antibodies.”
Choi, S. H., Yoo, S. S., Lee, S. Y., & Park, J. Y. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01382-6 · Cited by 41
“New classes of drugs that block other effectors of angiogenesis signaling pathways, such as VEGF receptors (VEGFRs), platelet-derived growth factors (PDGFs), fibroblast growth factors (FGFs), and angiopoietins (ANGs), have subsequently been developed, some of which are already being used in the treatment of cancer, in…”
BackgroundCavalu, S. D., Saber, S., Amer, A. E., Hamad, R. S., Abdel‐Reheim, M. A., Elmorsy, E. A., & Abdelhamid, A. M. (2024) · The FASEB Journal · doi:10.1096/fj.202400725rr · Cited by 38
“54–56 Moreover, a recent study demonstrated the apoptotic capability of propranolol in prostate and bladder cancer cell lines through activation of caspase-3 and encouraging the expression of BAX, Wee1, GADD153, and apoptosis-inducing factor.”
Sánchez-León, M. L., Jiménez‐Cortegana, C., Cabrera, G., Vermeulen, E. M., de la Cruz‐Merino, L., & Sánchez‐Margalet, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1050484 · Cited by 37
“Different immunotherapies have been developed in last decades, including treatments to target stromal cells (20), cell surface proteins (21), or angiogenic factors (22), among others.”
BackgroundYin, J., Dong, F., An, J., Guo, T., Cheng, H., Zhang, J., & Zhang, J. (2024) · Theranostics · doi:10.7150/thno.89306 · Cited by 41
Cheng, S., Zhang, S., Huang, M., Liu, Y., Zou, X., Chen, X., & Zhang, Z. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1411278 · Cited by 41
“…platelet-derived growth factor (PDGF), placental growth factor (PIGF), and hepatocyte growth factor (HGF), play essential roles in the activation of endothelial cells (ECs) and respond to and direct the migration of ECs in the direction of pro-angiogenic stimuli to promote neoangiogenesis (18).”
BackgroundAngiogenesis and EMT regulators in the tumor microenvironment in lung cancer and immunotherapy
Yan, T., & Shi, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1509195 · Cited by 40
Cellular and molecular basis of therapeutic approaches to breast cancer
El‐Tanani, M., Khatib, A. O. A., Al-Najjar, B. O., Shakya, A. K., El‐Tanani, Y., Lee, Y.-F., Serrano‐Aroca, Á., Mishra, V. K., Mishra, Y., Aljabali, A. A. A., et al. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110492 · Cited by 37
Vafopoulou, P., & Kourti, M. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.08 · Cited by 32
Ononin: A comprehensive review of anticancer potential of natural isoflavone glycoside
Sharma, U., Sharma, B., Mishra, A., Sahu, A., Mathkor, D. M., Haque, S., Raina, D., Ramniwas, S., Gupta, M., & Tuli, H. S. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23735 · Cited by 30
Therapeutic advancements in nanomedicine: The multifaceted roles of silver nanoparticles
Karunakar, K. K., Cheriyan, B. V., Krithikeshvaran, R., Gnanisha, M., & Abinavi, B. (2024) · Biotechnology Notes · doi:10.1016/j.biotno.2024.05.002 · Cited by 37
Yu, J., Li, M., Ren, B., Cheng, L., Wang, X., Ma, Z., Yong, W. P., Chen, X., Wang, L., & Goh, B. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1261575 · Cited by 34
“In HCC, STING agonists can induce the activation and maturation of DCs and reprogram immunosuppressive macrophages into immune-activating subtypes, thereby increasing CD8+ T cells in the TME (Jing et al., 2019; Chen C. et al., 2021).”
BackgroundInfluentialVascular Endothelial Growth Factor A VEGFA Inhibition: An Effective Treatment Strategy for Psoriasis
Chen, Y., Tai, Z., Zhu, C., Qin, Y., Zhu, Q., & Chen, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010059 · Cited by 35
Parasites revive hope for cancer therapy
Eissa, M. M., Salem, A. E., & Skhawy, N. E. (2024) · European journal of medical research · doi:10.1186/s40001-024-02057-2 · Cited by 31
Hoseinzadeh, A., Johari, H. G., Anbardar, M. H., Tayebi, L., Vafa, E., Abbasi, M., Vaez, A., Golchin, A., Amani, A. M., & Jangjou, A. (2022) · European journal of medical research · doi:10.1186/s40001-022-00833-6 · Cited by 32
“development of disordered and immature vasculature with damaged endothelial cell junctions, which is related to tumor interstitial fluid pressure, neo-vessel permeability, and fragility [155].”
BackgroundAnticancer potential of garlic bioactive constituents: Allicin, Z-ajoene, and organosulfur compounds
Talib, W. H., Atawneh, S., Shakhatreh, A. N., Shakhatreh, G. N., aljarrah, I. S. R., Hamed, R. A., banyyounes, D. A., & Al-Yasari, I. H. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e114556 · Cited by 50
Xie, M., Li, N., Xu, X., Xu, Y., Li, H., Zhu, L., Sheng, J., Zhou, Z., & Fan, Y. (2022) · Cancers · doi:10.3390/cancers14174333 · Cited by 29
Meybodi, S. M., Far, B. F., Pourmolaei, A., Baradarbarjastehbaf, F., Safaei, M., Mohammadkhani, N., & Samadani, A. A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02114-6 · Cited by 31
Endothelial cell in tumor angiogenesis: Origins, mechanisms, and therapeutic implication
Han, Y., Zhu, B., & Meng, S. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101611 · Cited by 42
The Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery
Bae, J., Choi, Y. S., Cho, G., & Jang, S. J. (2022) · Cancers · doi:10.3390/cancers14092144 · Cited by 27
Jędrzejewski, T., Pawlikowska, M., Sobocińska, J., & Wrotek, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054864 · Cited by 27
Targeting endothelial glycolytic reprogramming by tsRNA-1599 for ocular anti-angiogenesis therapy
Han, X., Kong, L.-J., Li, D., Tong, M., Li, X., Zhao, C., Jiang, Q., & Yan, B. (2024) · Theranostics · doi:10.7150/thno.96946 · Cited by 28
“Current anti-angiogenic treatments are highly dependent on anti-VEGF drugs [30, 31].”
Liang, Q., Peng, J., Xu, Z., Li, Z., Jiang, F., Ouyang, L., Wu, S., Fu, C., Liu, Y., Liu, Y., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.943006 · Cited by 27
“Anti-angiogenic therapy is a promising approach to combat cancers that restrains the nutrient and oxygen supply to cancer cells via decreasing the vascular network and avoiding the formation of new blood vessels (Lopes-Coelho et al., 2021).”
BackgroundAnti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation
Novi, S., Vestuto, V., Campiglia, P., Tecce, N., Bertamino, A., & Tecce, M. F. (2023) · Nutrients · doi:10.3390/nu15122748 · Cited by 27
Xu, X., Li, H., Tong, B., Zhang, W., Wang, X., Wang, Y., Tian, G., Xu, Z., & Zhang, G. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400204 · Cited by 32
Şen, Ö., Marino, A., Pucci, C., & Ciofani, G. (2021) · Materials Today Bio · doi:10.1016/j.mtbio.2021.100196 · Cited by 28
“In this process, the increased number of endothelial cells leads to form disorganized and immature vessels with disrupted endothelial cell junctions, associated with tumor neo-vessels permeability, fragility, and interstitial fluid pressure [4].”
The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview
Ionescu, C., Oprea, B., Ciobanu, G., Georgescu, M., Bica, R., Mateescu, G.-O., Huseynova, F., & Barragan‐Montero, V. (2022) · Medicina · doi:10.3390/medicina58070903 · Cited by 27
“In order to prevent the recurrence of tumors, their surgical resection followed by chemotherapy and/or radiotherapy represents the standard procedure constituting the pathway to an eventual cure [6,131].”
BackgroundInfluentialAptamers Versus Vascular Endothelial Growth Factor (VEGF): A New Battle against Ovarian Cancer
Mishra, Y., Chattaraj, A., Mishra, V. K., Ranjan, A., & Tambuwala, M. M. (2023) · Pharmaceuticals · doi:10.3390/ph16060849 · Cited by 29
“Pembrolizumab, nivolumab, toripalimab, sintilimab, atezolizumab, durvalumab, and ipilimumab are the principal inhibitors utilized for first-line cancer therapy [48].”
BackgroundRational design of siRNA-based delivery systems for effective treatment of brain diseases
Lu, D., Sun, Y., Luan, Y., & He, W. (2024) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2024.100041 · Cited by 28
“In clinical practice, targeted therapies that speci fi cally inhibit angiogenesis are commonly used to slow tumor growth [59].”
Progress in nanomedicine for sonodynamic immunotherapy of tumors
Feng, Z., Wang, Z., Xiang, X., Wang, L., Du, F., Xiao, X., Zhu, B., Rong, X., & Qiu, L. (2024) · EngMedicine · doi:10.1016/j.engmed.2024.100027 · Cited by 25
Skubal, M., Larney, B. M., Phung, N. B., Desmaras, J. C., Dozic, A. V., Volpe, A., Ogirala, A., Machado, C. M. L., Djibankov, J., Ponomarev, V., et al. (2024) · Theranostics · doi:10.7150/thno.95334 · Cited by 26
“The investigation of resistance to anti-vascular biology is essential to improve vascular targeted therapies [50].”
Jordan, A. M., Drake, R. J. G., & Hodivala‐Dilke, K. (2025) · Physiological Reviews · doi:10.1152/physrev.00046.2024 · Cited by 31
Wang, Y., Jiang, C., Zhou, H., & Han, R. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00705-9 · Cited by 30
[15O]H2O PET: Potential or Essential for Molecular Imaging?
Slart, R. H. J. A., Martínez-Lucio, T. S., Boersma, H. H., Borra, R., Cornelissen, B. T., Dierckx, R., Dobrolińska, M. M., Doorduin, J., Erba, P. A., Glaudemans, A. W. J. M., et al. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.08.002 · Cited by 31
“88 Angiogenesis, the process in which new blood vessels originate from existing vasculature, is essential for tumor growth, progression, and development of metastases, 89,90 leading to increased blood fl ow in the tumor.”
BackgroundEgorova, A., Maretina, M. A., Krylova, I., & Kiselev, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010013 · Cited by 24
“Numerous applications of anti-angiogenic therapy have been reported to date, particularly in the treatment of solid tumors [1].”
BackgroundKhafaga, A. F., Gaballa, M. M. S., Karam, R., Shoulah, S., Shamma, R. N., Khalifa, N. E., Farrag, N. E., & Noreldin, A. E. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122499 · Cited by 25
Wang, Y. (2024) · Phytotherapy Research · doi:10.1002/ptr.8215 · Cited by 24
Zhang, Y., Sun, M., He, Y., Gao, W., Wang, Y., Yang, B., Sun, Y., & Kuang, H. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132617 · Cited by 28
Alaa, R. S. A. E., Al-Mannai, W., Darwish, N., & Al-Mansoori, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111558 · Cited by 27
Dual faces of angiogenesis: Mechanisms and therapeutic applications
Izadpanah, R., Izadpanah, A., & Alt, E. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189494 · Cited by 31
Advances in tumor-associated macrophage-mediated chemotherapeutic resistance in glioma
Liu, X., & Yu, Q. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1676338 · Cited by 25
Wu, P., Zhang, J., Jiang, Z., Liu, X., Jiang, N., Zou, J., Chen, X., Wu, D., & Li, Y. (2026) · Biomarker Research · doi:10.1186/s40364-026-00898-z · Cited by 22
“These structural defects lead to increased vascular permeability and inefficient perfusion, collectively fostering a unique tumor microenvironment (TME) marked by hypoxia, low pH, and high lactate levels [4].”
Wang, J., Liu, Y., Zhang, Y., Li, X., Fang, M., & Qian, D. (2023) · Cancer Medicine · doi:10.1002/cam4.5941 · Cited by 21
Kidney cancer: From tumor biology to innovative therapeutics
Rinaldi, L., Senatore, E., Feliciello, S., Chiuso, F., Insabato, L., & Feliciello, A. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189240 · Cited by 28
Reaching new lights: a review on photo-controlled nanomedicines and their in vivo evaluation
Remmers, R. C. P. A., & Neumann, K. (2023) · Biomaterials Science · doi:10.1039/d2bm01621d · Cited by 20
Thomas, N. M., Alharbi, M., Muripiti, V., & Banothu, J. (2025) · Molecular Diversity · doi:10.1007/s11030-024-11092-4 · Cited by 29
“Modern treatment modalities, such as hormone therapy, anti-angiogenic therapy, stem cell therapy, and immuno-therapy, offer promising alternatives with fewer side effects and improved efficacy [6].”
Garemilla, S. S. S., Gampa, S. C., & Garimella, S. V. (2025) · Medical Oncology · doi:10.1007/s12032-025-02754-w · Cited by 21
Interleukin-17A in diabetic retinopathy: The crosstalk of inflammation and angiogenesis
Li, J., Zhao, T., & Sun, Y. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116311 · Cited by 20
Design and Application of Hybrid Polymer-Protein Systems in Cancer Therapy
Sun, Q., Yang, Z., & Qi, X. (2023) · Polymers · doi:10.3390/polym15092219 · Cited by 18
Investigation of Lupeol as Anti-Melanoma Agent: An In Vitro-In Ovo Perspective
Bociort, F., Macasoi, I. G., Marcovici, I., Motoc, A. G. M., Grosu, C., Pînzaru, I., Petean, C., Avram, Ș., & Dehelean, C. A. (2021) · Current Oncology · doi:10.3390/curroncol28060425 · Cited by 18
Zhang, Y., Zhen, F., Sun, Y., Han, B., Wang, H., Zhang, Y., Zhang, H., & Hu, J. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04438-3 · Cited by 18
“At present, anti-angiogenic therapy mainly relies on targeting VEGF/VEGFR or PDGF/PDGFR [6, 58].”
BackgroundAngioprevention of Urologic Cancers by Plant-Derived Foods
García‐Caballero, M., Torres‐Vargas, J. A., Marrero, A. D., Martínez-Poveda, B., Medina, M. Á., & Quesada, A. R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020256 · Cited by 20
Ismail, C. A., Eissa, M. M., Gaafar, M. R., Younis, L. K., & Skhawy, N. E. (2023) · Medical Oncology · doi:10.1007/s12032-023-01994-y · Cited by 17
“Thus, VEGF level correlates with Treg cell population, while inversely correlates with CD8+ T cells within the tumor [48].”
BackgroundEissa, M. M., Gaafar, M. R., Younis, L. K., Ismail, C. A., & Skhawy, N. E. (2023) · Infectious Agents and Cancer · doi:10.1186/s13027-023-00500-3 · Cited by 17
“Additionally, VEGF is a powerful promoter of immunosuppression that directly correlates with Treg population while inversely corelates with CD8+ cytotoxic T cell population [48].”
BackgroundWang, Z., Chen, G., Yuan, D., Wu, P., Guo, J. X., Lu, Y., & Wang, Z. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24464 · Cited by 17
“Recognizing the importance of angiogenesis in tumor progression, some scholars proposed the concept of ‘anti-angiogenic therapy ’ [25 – 27].”
BackgroundNanoparticle‐Based drug delivery strategies for targeted therapy to hypoxic solid tumors
Wu, Z., Chen, J., Wang, B., Wen, Q., & Fu, S. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.158081 · Cited by 19
Mechanisms of breast cancer metastasis: the role of extracellular matrix
Chen, R., Zhang, R., Ke, F., Guo, X., Zeng, F., & Liu, Q. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05175-x · Cited by 21
“The formation of neo-vasculature is essential for tumor growth, with these vessels being more distorted and immature compared to those in normal tissues [177].”
The mechanistic role of NAT10 in cancer: Unraveling the enigmatic web of oncogenic signaling
Rodrigues, P., Bangali, H., Ali, E., Абдрешов, С. Н., Hjazi, A. M., Fenjan, M. N., Alawadi, A. H., Alsaalamy, A. H., Alasheqi, M. Q., & Mustafa, Y. F. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154990 · Cited by 17
Tissue‐Penetrating Ultrasound‐Triggered Hydrogel for Promoting Microvascular Network Reconstruction
Zhao, Z., Zhang, Y., Chen, M., Xie, X., Cui, W., & Zuo, K. (2024) · Advanced Science · doi:10.1002/advs.202401368 · Cited by 24
Sadr, S., Hajjafari, A., Rahdar, A., Pandey, S., Jafroodi, P. P., Lotfalizadeh, N., Soroushianfar, M., Kavasebi, S. S., Kharaba, Z. J., Fathi‐karkan, S., et al. (2024) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2024.100238 · Cited by 16
Işık, Ş., Özçeşmeci, M., Burat, A. K., Hamuryudan, E., Can, O., & Serhatlı, M. (2025) · Scientific Reports · doi:10.1038/s41598-024-84674-9 · Cited by 16
Vascular mimicry as a facilitator of melanoma brain metastasis
Provance, O. K., Oria, V. O., Tran, T. T. T., Caulfield, J. I., Zito, C. R., Aguirre, A., Schalper, K. A., Kluger, H. M., & Jilaveanu, L. B. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05217-z · Cited by 18
“Current therapies inhibiting tumor neovascularization target pro-angiogenic growth factors including, but not limited to, vascular endothelial growth factor (VEGF) and their receptors (VEGF-receptors) [34, 35].”
Strategies for the prevention or reversal of PARP inhibitor resistance
Mitri, Z. I., Goodyear, S. M., & Mills, G. B. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2393251 · Cited by 18
“This mechanistic rationale, coupled with minimal overlapping toxicity led to the investigation of the combination of PARPi and anti-angiogenic agents (Table 3), with the majority of clinical trials occurring in the ovarian cancer space [120].”
Oni, M. I. J., Bhuia, M. S., Chowdhury, R., Sheikh, S., Munshi, M. H., Hasan, M. S. A., & Islam, M. T. (2024) · Journal of Food Biochemistry · doi:10.1155/2024/8843855 · Cited by 18
Chen, Y.-C., Hsu, C., Wang, H., Wu, S., Chang, Y., Chen, J., Wu, Y., Lin, Y., Yang, C., Lin, M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0821 · Cited by 19
“In addition, there are well-known therapies that target vasculature in the TME, such as antiangiogenic agents and agents that promote vessel normalization (61, 62).”
Context Matters: Response Heterogeneity to Collagen-Targeting Approaches in Desmoplastic Cancers
Fuller, A. M., & Eisinger‐Mathason, T. S. K. (2022) · Cancers · doi:10.3390/cancers14133132 · Cited by 16
Tumor vessel normalization and immunotherapy in gastric cancer
Yu, X., He, S., Shen, J., Huang, Q., Peng, Y., Huang, L., Pu, D., Wang, L., Li, L., Liu, J., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221110176 · Cited by 15
Ileiwat, Z. E., Tabish, T. A., Zinovkin, D. A., Yüzügülen, J., Arghiani, N., & Pranjol, M. Z. I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.976677 · Cited by 15
Shedding light on a mysterious link between Toxoplasma gondii and cancer: A review
Skhawy, N. E., & Eissa, M. M. (2023) · Experimental Parasitology · doi:10.1016/j.exppara.2023.108544 · Cited by 14
Metadata
- Authors
- Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J.
- Affiliations
- Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal
- Instituto Português de Oncologia Francisco Gentil (PT)
- Universidade Nova de Lisboa (PT)
- Corresponding author
- Serpa, Jacinta
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-05
- Volume
- 22
- Issue
- 7
- Pages
- 3765
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8038573
- OpenAlex
- W3140967360
- Cited by
- 416
- References
- 246
- Citations by year
- 2026: 61 · 2025: 98 · 2024: 117 · 2023: 86 · 2022: 46 · 2021: 8
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministério da Educação e Ciência
- Ministério da Ciência, Tecnologia e Ensino Superior
- Ministério da Educação
- Fundação para a Ciência e a Tecnologia (/2017, iNOVA4Health, PD/BD/128337/2017)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, angiogenesis, VEGF signaling, tumor microenvironment, cancer immunotherapy, immunosuppression, drug repurposing, combination therapy, tumor vasculature, treatment resistance
- MeSH terms
- Animals, Humans, Neoplasm Proteins, Neoplasms, Neovascularization, Pathologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.